rosiglitazone has been researched along with Alloxan Diabetes in 167 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.20) | 18.2507 |
| 2000's | 60 (35.93) | 29.6817 |
| 2010's | 96 (57.49) | 24.3611 |
| 2020's | 9 (5.39) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Ayscue, AH; Henke, BR; Lambert, MH; Leesnitzer, LM; Liu, KG; Oliver, WR; Plunket, KD; Sternbach, DD; Willson, TM; Xu, HE | 1 |
| Barbe, J; da Costa Leite, LF; da Rocha Pitta, I; de Assis Rocha Neves, F; de Lima, Mdo C; Galdino, SL; Hernandes, MZ; Veras Mourão, RH; Vidal, S | 1 |
| Cap, M; Chang, C; Cheng, PT; Chu, C; Devasthale, P; Doweyko, AM; Farrelly, D; Gu, L; Hariharan, N; Harrity, T; Hosagrahara, V; Kadiyala, P; Kunselman, L; Lippy, J; Locke, K; Morgan, N; Muckelbauer, J; O'Malley, K; Ponticiello, R; Ryono, D; Wang, W; Zahler, R; Zebo, R; Zhang, L | 1 |
| Chen, ML; Leng, Y; Shen, JH; Shen, Y; Tang, J; Xu, TF; Ye, YL; Yin, HZ; Zhou, Z; Zou, HJ | 1 |
| Bai, X; Chen, J; Chen, X; Fang, J; Liu, Y; Wen, L; Ye, M | 1 |
| Chen, W; Fan, S; Li, S; Wang, L; Xie, Y; Xu, C; Zhong, W; Zhou, X | 1 |
| Bhatia, G; Kumar, A; Maurya, RA; Sharma, S; Srivastava, AK; Srivastava, SP; Tamrakar, AK; Tripathi, VD | 1 |
| Ahmad, P; Gupta, LP; Kumar, A; Rahuja, N; Sharma, S; Srivastava, AK; Srivastava, SP; Tamrakar, AK | 1 |
| Dwivedi, AK; Nath, C; Pratap, R; Raghubir, R; Satyanarayana, M; Singh, AB; Singh, H; Singh, SK; Srivastava, AK; Srivastava, M; Srivastava, SP; Tiwari, P; Verma, AK | 1 |
| Adimulam, LS; Akula, A; Anagani, SR; Avupati, VR; Doddi, BR; Guntuku, GS; Vutla, VR; Vyricharla, AK; Yejella, RP | 1 |
| Aramaki, H; Beckmann, H; Biermann, D; Chen, JL; Cushing, TD; Flygare, J; Frankmoelle, W; Furukawa, N; Hagiwara, A; Houze, JB; Iida, T; Jaen, J; Kearney, P; Kitao, Y; Learned, MR; Li, Y; Lindstrom, M; Liu, J; McGee, LR; Miao, S; Motani, A; Nakamura, M; Nishiu, J; Rubenstein, SM; Shinkai, H; Taygerly, JP; Thoolen, M; Timmermans, PB; Walker, N; Wang, Z; Weiszmann, J; Ye, G | 1 |
| Guo, C; Guo, S; Jiang, B; Shi, D; Wang, T | 1 |
| Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, KK; Yar, MS | 1 |
| Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, KK; Shafi, S; Yar, MS | 1 |
| Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Javed, K; Kharbanda, C; Nazreen, S; Pasha, MA; Shafi, S | 1 |
| Fan, L; Li, Z; Ma, X; Tang, L; Wang, J; Wu, H; Xiao, W; Zhong, G | 1 |
| Gim, HJ; Jeon, R; Jeong, JH; Lee, SJ; Li, H; Oh, SJ; Park, BH; Ryu, JH; Song, MY; Sung, MK | 1 |
| Alam, MS; Ali, Y; Bano, S; Dhulap, A; Hamid, H; Javed, K; Kharbanda, C | 1 |
| Kanojiya, S; Maurya, R; Mishra, A; Pandey, J; Patel, OP; Raju, KS; Saini, D; Shukla, SK; Srivastava, AK; Srivastava, MN; Tamrakar, AK; Taneja, I; Wahajuddin, M; Yadav, PP | 1 |
| Belin, RM; Brooks, DA; Cannady, EA; Cardona, GR; Chen, K; Chen, Q; Chen, Y; Coffey, DS; Deeg, MA; Eessalu, TE; Ficorilli, JV; Haas, JV; Hamdouchi, C; Johnson, JT; Kahl, SD; Lineswala, JP; Ma, X; Maiti, P; Marcelo, MC; Montrose-Rafizadeh, C; Otto, KA; Patel Lewis, A; Piper, JL; Pratt, EJ; Reifel Miller, A; Sweetana, SA; Wilbur, KL; Yumibe, NP; Zink, RW | 1 |
| Alesawy, MS; Eissa, IH; ElSohly, MA; Ibrahim, MK; Metwaly, AM; Radwan, MM | 1 |
| Askari, HB; Beauchamp, DA; Cheung, W; Gaul, MD; Geisler, JG; Huang, H; Kasturi, J; Liu, J; Patch, RJ; Patel, S; Player, MR; Rentzeperis, D; Towers, M; Xu, G; Zhao, BP | 1 |
| Bell, A; Clapper, W; Gunnet, J; Haug, P; Hua, H; Huebert, N; Jenkinson, C; Koudriakova, T; Leonard, J; Murray, WV; Suckow, A; Sui, Z; Wall, M; Wang, Y; Winters, MP; Yan, W | 1 |
| Deng, F; Li, Y; Li, Z; Zhang, D; Zhang, L; Zhou, Z | 1 |
| Kong, WJ; Li, YH; Niu, TY; Pang, YD; Song, DQ; Tang, S; Wang, C; Wang, YX; Zhang, YH | 1 |
| Gu, YH; Hou, DL; Li, HB; Liu, K; Qi, X; Xu, QL; Zhao, X | 1 |
| Chen, J; Huang, F; Li, Y; Su, Y; Wu, C; Yan, Z; Yang, Q; Yu, H; Yu, L; Zeng, Z; Zhang, W; Zhang, XK; Zhou, H | 1 |
| Cai, Z; Han, J; Li, Z; Ren, Q; Wang, B; Zhang, L; Zhou, Z | 1 |
| Liu, JH; Liu, YY; Ruan, HJ; Song, CR; Sui, YL; Zhao, C; Zhu, JZ | 1 |
| Ahsan, W; Alam, MS; Albratty, M; Alhazmi, HA; Azam, F; Haque, A; Meraya, AM; Najmi, A; Taha, MME; Thangavel, N | 1 |
| Haroun, M | 1 |
| Dong, X; Fang, G; Huang, C; Huang, J; Huang, Y; Luo, D | 1 |
| Flatt, PR; Moffett, RC; Sarnobat, D; Tarasov, AI | 1 |
| Ateyya, H; El-Sherbeeny, NA; Nader, MA | 1 |
| Jeong, SY; Kang, S; Kim, DS; Park, S | 1 |
| Mahboob, T; Tabassum, A | 1 |
| Katyal, A; Mehta, V; Patel, SS; Ray, RS; Sharma, A; Udayabanu, M | 1 |
| Mahboob, T; Tabassum, A; Yasmeen, K; Zaidi, SNF | 1 |
| Bandyopadhyay, S; Chattopadhyay, N; Gayen, JR; Gupta, AP; Gupta, K; Kamthan, M; Kushwaha, R; Mishra, J; Vishwakarma, J | 1 |
| Duan, Y; Fu, X; Gao, H; Liu, Y; Xie, C; Xie, H; Yuan, H; Zhou, M | 1 |
| Gluch-Lutwin, M; Librowski, T; Nawiesniak, B; Sałat, K | 1 |
| Hasan, SM; Khan, MI; Sadeque, MZ; Umar, BU | 1 |
| Ezhumalai, M; Pugalendi, KV; Radhiga, T | 1 |
| Azeloglu, EU; Badimon, JJ; Benard, L; Chen, Y; Giannarelli, C; Goldfarb, J; Gottesman, O; Hajjar, RJ; Iyengar, R; Nishimura, T; Zafar, MU; Zhao, S | 1 |
| Chen, LJ; Cheng, JT; Cherng, YG; Hsu, CT; Huang, KC | 1 |
| Al-Dhubiab, BE; Chattopadhyaya, I; Gupta, A; Gupta, S; Kumria, R; Nair, A | 1 |
| Patel, SS; Udayabanu, M | 1 |
| Bland, JS; Darland, G; Desai, A; Grayson, N; Konda, VR | 1 |
| Arkell, AM; Beaudoin, MS; Holloway, GP; Simpson, JA; Snook, LA; Stefanson, A; Wan, Z; Wright, DC | 1 |
| Abou Daya, K; Abu Daya, H; Nahhas, G; Nasser Eddine, M; Nuwayri-Salti, N | 1 |
| Chen, LJ; Cheng, MF; Ku, PM; Lin, JW | 1 |
| Korantzopoulos, P; Li, G; Li, J; Liu, T; Zhao, H | 1 |
| Li, YX; Sun, Q; Zeng, JB; Zhang, Y | 1 |
| Kuo, YH; Lin, CH; Shih, CC | 1 |
| Gad, HI | 1 |
| Barakat, W; El-Maraghy, N; Reda, E; Saleh, S | 1 |
| Olsson, IA; Varga, OE; Zsíros, N | 1 |
| Shieh, KR; Tseng, HL; Yang, SC; Yang, SH | 1 |
| Chen, M; Feng, T; Han, X; Li, N; Li, Y; Liu, C; Liu, P; Si, S; Wang, X; Xu, Y; Zhu, N | 1 |
| Alam, MM; Alam, MS; Alam, P; Ali, Y; Bano, S; Dhulap, A; Haider, S; Hamid, H; Kharbanda, C; Nazreen, S; Pasha, MA; Pillai, K; Shahar Yar, M | 1 |
| Goto, T; Kato, H; Maruta, K; Nagamine, J; Nagata, R; Nakayama, R; Takata, M; Takazawa, T; Tsuchida, A; Watanabe, K; Yamanaka, M | 1 |
| Bing, X; Fei, L; Jun, L; Qian-qian, S; Shuang, W; Yong-Jun, H; Zhang-Min, M | 1 |
| Kavimani, S; Kesavanarayanan, KS; Prathiba, D; Priya, RJ; Selvakkumar, C | 1 |
| Feng, Y; Shi, LL; Wang, LY; Wang, Y; Xu, JW | 1 |
| Hasegawa-Moriyama, M; Inada, E; Kanmura, Y; Kurimoto, T; Saito, T; Yamada, T | 1 |
| Guo, F; Liu, L; Song, W; Wang, Q; Xiong, L; Yang, R; Zhong, H | 1 |
| Chao, CY; Hsu, CC; Kuo, YH; Li, PY; Tang, FY; Yin, MC | 1 |
| Gupta, S; Patel, SS; Udayabanu, M | 1 |
| Dong, Z; Duan, H; Ji, X; Jiang, P; Li, M; Li, X; Ma, B; Ma, X; Ni, Z; Wang, B; Wei, Q | 1 |
| Andrisani, OM; Bi, P; Bidwell, CA; Castro, B; Durkes, A; Elzey, BD; Freeman, JL; Karki, A; Konieczny, SF; Kuang, S; Wang, C; Wirbisky, SE; Yue, F | 1 |
| Carvalho, VF; E Silva, PM; Magalhães, NS; Martins, MA; Torres, RC | 1 |
| Hong, SM; Kim, YS; Kwon, DY; Park, S | 1 |
| Brosius, FC; Feldman, EL; Kretzler, M; Pennathur, S; Sullivan, KA; Wiggin, TD | 1 |
| Hirschberg, DL; Huang, M; Li, Z; Nestorova, G; Quertermous, T; Tsao, P; Wagner, R; Wilson, KD; Wu, JC; Yock, PG; Yue, P | 1 |
| Brosius, FC; Byun, J; Feldman, EL; Kennedy, RT; Kretzler, M; Lorenz, M; Pennathur, S; Saha, J; Schin, M; Zhang, H | 1 |
| Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
| Chen, HS; Juan, CC; Lin, HD; Wu, TE | 1 |
| Asad, M; Nivitabishekam, SN; Prasad, VS | 1 |
| Bolkent, S; Sundler, F; Yildirim, S | 1 |
| Chen, Y; Jimbu, YM; Lu, YL; Yang, H; Ye, TT; Zhao, JB | 1 |
| Chen, K; Chen, Y; Li, XC; Wang, YX; Yao, XM; Ye, SD; Zai, ZM | 1 |
| Srivastava, RA | 1 |
| Chen, K; Chen, Y; Li, S; Qian, Y; Yang, G; Ye, S; Zhai, Z | 1 |
| Ahn, CW; Cha, BS; Kim, HJ; Kim, SK; Lee, HC; Lee, YJ; Ma, ZA; Shim, WS; Zhao, Z | 1 |
| Bai, X; Chen, J; Chen, X; Fang, J; Liu, Y; Tian, L; Zhou, J; Zhou, Q | 1 |
| Hui, X; Kraegen, EW; Lam, KS; Li, Y; Wang, Y; Wu, D; Xu, A; Zhang, J; Zhu, W | 1 |
| Feng, CR; He, QJ; Lou, YJ; Wu, HS; Yang, B; Zhou, CX; Zhu, DF | 1 |
| Brûlé, S; Chewchuk, S; Houde, V; Lavigne, C; Liu, Y; Marette, A; Pilon, G; Sweeney, G; Xu, A | 1 |
| Au, WS; Chow, BK; He, ML; Ko, OK; Kung, HF; Lin, MC; Liu, CC; Lu, LW; Ng, SS; Tam, S; Yeung, CM | 1 |
| Abdel-Gaber, SA; Ashour, OM; Fouad, AA; Morsy, MA | 1 |
| Arnol, V; Cortizo, AM; Gangoiti, MV; McCarthy, AD; Molinuevo, MS; Schurman, L; Sedlinsky, C; Tolosa, MJ | 1 |
| An, ZM; Liu, GY | 1 |
| Gupta, S; Hrishikeshvan, HJ; Sehajpal, PK | 1 |
| AbdelGawad, H; Baraka, A | 1 |
| Cruzado, JM; Flaquer, M; Franquesa, M; Grinyó, JM; Herrero-Fresneda, I; Lloberas, N; Rosa, JL; Torras, J; Vidal, A | 1 |
| Auwerx, J; Houtkooper, RH | 1 |
| Banks, AS; Blüher, M; Boström, P; Chalmers, MJ; Choi, JH; Estall, JL; Griffin, PR; Kajimura, S; Kamenecka, TM; Laznik, D; Ruas, JL; Spiegelman, BM | 1 |
| Choi, JE; Choi, JM; Kim, DH; Kim, SW; Lee, WJ; Park, JS; Yoon, SY | 1 |
| Gang, GT; Hwang, JH; Kim, YH; Lee, CH; Noh, JR; Yang, KJ; Yang, SJ; Yeom, YI | 1 |
| Barone, F; Bilous, R; Buckingham, R; Dessapt, C; Gnudi, L; Gruden, G; Hayward, A; Hiroshi, K; Setti, G; Viberti, G; White, K | 1 |
| Zhou, JY; Zhou, SW | 2 |
| Ayanoğlu-Dülger, G; Çelikel, Ç; Elçioğlu, HK; Kabasakal, L; Özkan, N | 1 |
| Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY | 1 |
| Li, P; Liu, K; Shi, Y; Xu, X; Zheng, Z; Zhu, B | 1 |
| Ahmed, D; Pillai, KK; Sharma, M | 1 |
| Hoo, RL; Huang, Y; Lam, KS; Lau, CW; Lee, VW; Tian, XY; Vanhoutte, PM; Wang, Y; Wong, WT; Xu, A; Yu, J | 1 |
| Itoh, N; Ohkura, N; Oishi, K; Tomita, T | 1 |
| Chen, Y; Jiang, BR; Lu, YL; Qiao, J; Wang, NJ; Yang, LZ; Ye, TT; Yu, J; Zhao, LJ | 1 |
| Kim, DS; Kim, HJ; Kim, JH; Kim, JS; Park, S | 1 |
| Wang, X | 1 |
| Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W | 1 |
| Abd el-Latif, FF; Khalifa, M; Sayed, AA | 1 |
| Hu, W; Liu, D; Yu, Q; Zhang, J | 1 |
| Gujarathi, NA; Patel, JK; Rane, BR | 1 |
| Pan, D; Pan, LF; Teng, BS; Wang, CD; Wu, JS; Yang, HJ; Zhang, D; Zhou, P | 1 |
| Guo, Z; Li, J; Qin, Z; Yin, Y; Zhang, R | 1 |
| Abo-Warda, SM; El-Bassossy, HM; Fahmy, A | 1 |
| Batista, MM; Carvalho, VF; Cordeiro, RS; E Silva, PM; Martins, MA; Pons, AH; Silva, AR; Torres, RC | 1 |
| Das, N; Kumar, P; Moorthy, NS; Shrivastava, SK; Shukla, S; Srivastava, RS; Trivedi, P | 1 |
| Feng, Y; Ruan, KF; Wang, LY; Wang, S; Wang, Y; Xu, DS | 1 |
| Dugina, JL; Epstein, OI; Kheyfets, IA; Spasov, AA; Voronkova, MP | 1 |
| Ayaz, L; Emre, M; Kavak, S | 1 |
| Dong, L; Gao, J; Hu, M; Qu, X; Zhang, X; Zhao, S | 1 |
| Choi, MG; Jung, JS; Kang, YJ; Kim, CH; Kim, SJ; Kim, SS; Park, SH; Ryu, OH; Sim, YB; Suh, HW | 1 |
| Bigley, AL; Jones, HB; Pemberton, J; Randall, KJ | 1 |
| Fan, B; Li, G; Liang, S; Liu, S; Peng, H; Qin, S; Qiu, S; Tu, G; Xu, H; Xu, W; Yu, S; Zheng, C; Zhu, Q; Zhu, S | 1 |
| Khazaei, M; Salehi, E | 1 |
| Christensen, LP; Kristiansen, K; Rimbach, G; Schrader, E; Wein, S; Wolffram, S | 1 |
| Aston-Mourney, K; Brooks-Worrell, BM; Hull, RL; Subramanian, SL; Taborsky, GJ; Udayasankar, J; Zraika, S | 1 |
| Cohen, H; Dvir, A; Gerber, Y; Harats, D; Levi, Z; Levkovitz, H; Ravid, M; Rhachmani, R; Shaish, A; Trestman, S; Yacov, N | 1 |
| Bosco, AA; Lerario, AC; Santos, RF; Wajchenberg, BL | 1 |
| Battell, ML; Bhanot, S; McNeill, JH; Orvig, C; Yuen, VG | 1 |
| Cline, GW; Davies, PJ; Leibowitz, MD; Shen, Q; Shulman, GI | 1 |
| Roden, M; Stingl, H | 1 |
| Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E | 1 |
| Barr, R; Bensch, WR; Brozinick, JT; Bull, C; Dana, S; Hawkins, E; Klausing, K; Martin, JA; Otto, K; Rafaeloff-Phail, R; Rafizadeh-Montrose, C; Reifel-Miller, A; Rhodes, G; Robey, R; Rojo, I; Rungta, D; Snyder, D; Warshawsky, A; Wilbur, K; Zhang, T; Zink, R | 1 |
| Ahn, KO; Choi, YH; Chung, BH; Ito, S; Kim, J; Li, C; Lim, SW; Sugawara, A; Sun, BK; Yang, CW; Yang, JH; Yoon, KH | 1 |
| Ouyang, JP; Wang, SS; Wen, CY; Wu, K; Wu, Y; Xia, ZY | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Smith, CM | 1 |
| Barbe, J; Galdino, SL; Lima, MC; Lima, VL; Mourão, RH; Pitta, IR; Santos, JN; Silva, TG; Soares, AL; Vieira, ES | 1 |
| Chen, X; Cryan, E; Demarest, KT; Osborne, MC; Rybczynski, PJ; Tang, Y; Xu, J; Yang, M; Zeck, R; Zhou, L | 1 |
| Abdel-Salam, OM; Baiuomy, AR; El-Batran, SA; Nofal, SM | 1 |
| Bilban, M; Loffler, M; Reimers, M; Stulnig, TM; Waldhäusl, W | 1 |
| Adler, S; Banz, WJ; Davis, J; Henry, N; Higginbotham, DA; Hou, Y; Meyers, CY; Oitker, J; Peterson, R; Steinle, JJ; Winters, TA | 1 |
| Fan, L; Forudi, F; Lincoff, AM; Penn, MS; Qu, W; Schmidt, AM; Topol, EJ; Wang, K; Zhang, M; Zhou, X; Zhou, Z | 1 |
| Hiramatsu, Y; Masumoto, A; Masuyama, H; Suwaki, N; Takamoto, N | 1 |
| Lu, YL; Wang, NC; Wang, XF; Wang, YN; Wu, H; Yu, DL; Zhang, L; Zhao, JB; Zhu, L | 1 |
| Hu, CP; Jiang, JL; Li, YJ; Wang, S; Yang, DL; Zhang, XJ | 1 |
| Araie, M; Iriyama, A; Kadowaki, T; Kubota, N; Muranaka, K; Tamaki, Y; Terauchi, Y; Usui, T; Yanagi, Y | 1 |
| Boakye, K; Bullock, WH; Burns, M; Cantin, LD; Clark, R; Claus, T; Daly, M; delaCruz, FE; Ehrgott, FJ; Iwuagwu, CI; Johnson, JS; Keiper, C; Liang, S; Livingston, JN; Ma, X; Ogutu, H; Schoenleber, RW; Shapiro, J; Town, C; Tsutsumi, M; Yang, L | 1 |
| Chen, LM; Duan, L; Li, H; Li, XW; Li, Y; Qin, Y; Wen, YB | 1 |
| Bansal, VS; Davis, JA; Dhar, A; Khanna, V; Mahajan, DC; Mittra, S; Priyadarsiny, P; Roy, S; Saini, KS; Sattigeri, J; Singh, S | 1 |
| Bao, Y; Jia, RH; Li, J; Yuan, J | 1 |
| Li, Y; Liu, MY; Wang, YG | 1 |
| Jatwa, R; Kar, A; Panda, S; Parmar, HS | 1 |
| Itakura, Y; Nakagawa, T; Noguchi, H; Taiji, M; Tsuchida, A; Yamanaka, M | 1 |
| Chin-Dusting, J; Cooper, ME; Jandeleit-Dahm, KA; Kling, D; Mizrahi, J; Murphy, A; Sebokova, E; Sheehy, K; Tikellis, C; Woollard, KJ | 1 |
| Emre, M; Günay, I; Kavak, S; Kavak, T; Kolcu, Z; Tetiker, T | 1 |
| Ayaz, L; Emre, M; Günay, I; Inal, T; Kavak, S; Tamer, L | 1 |
| Kadowaki, T | 1 |
| Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ | 1 |
| Collins, AR; Hsueh, WA; Kawano, Y; Nicholas, SB; Wakino, S | 1 |
| Boehm, M; Crombie, DL; Davies, PJ; Depre, C; Heyman, RA; Leibowitz, MD; Liu, S; Nagy, L; Singh Ahuja, H; Tontonoz, P | 1 |
| Berger, J; Elbrecht, A; Hermanowski-Vosatka, A; Moller, DE; Tanen, M; Thieringer, R; Wright, SD | 1 |
| Berrebi-Bertrand, I; Bril, A; Buckingham, RE; Delerive, P; Khandoudi, N; Staels, B | 1 |
4 review(s) available for rosiglitazone and Alloxan Diabetes
| Article | Year |
|---|---|
Estimating the predictive validity of diabetic animal models in rosiglitazone studies.
Topics: Animal Nutritional Physiological Phenomena; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Sex Characteristics; Species Specificity; Thiazolidinediones | 2015 |
Assessment of cardiac safety for PPARγ agonists in rodent models of heart failure: a translational medicine perspective.
Topics: Animals; Biomarkers; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Profiling; Heart Failure; Hypoglycemic Agents; Kidney; Myocardial Infarction; PPAR gamma; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical | 2012 |
[Future targets in the treatment of type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycated Hemoglobin; Glycogen Synthase Kinase 3; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Peroxidation; Metabolic Syndrome; Mice; Oxazines; Peptide Fragments; Phenylpropionates; Protein Precursors; Rats; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors | 2004 |
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
163 other study(ies) available for rosiglitazone and Alloxan Diabetes
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Molecular Weight; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tyrosine | 2001 |
Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.
Topics: Alloxan; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Hydrogen Bonding; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Mice; Models, Molecular; Molecular Structure; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2007 |
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Topics: Administration, Oral; Animals; Azetidines; Biological Availability; Copper; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental; Dyslipidemias; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glucose; Mice; Mice, Mutant Strains; Molecular Structure; PPAR alpha; PPAR gamma; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Triglycerides | 2008 |
Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Body Weight; Diabetes Mellitus, Experimental; Fats; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Mice; Models, Molecular; Obesity; Phenylpropionates; PPAR gamma; Rats; Rats, Wistar | 2009 |
Hypoglycemic polysaccharides from the tuberous root of Liriope spicata.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Liriope Plant; Mice; Molecular Structure; Plant Roots; Plants, Medicinal; Polysaccharides | 2009 |
(S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Lipids; Mice; PPAR alpha; PPAR gamma; Propionates | 2010 |
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Dyslipidemias; Glycogen Phosphorylase; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Quinolines | 2010 |
Synthesis of propiophenone derivatives as new class of antidiabetic agents reducing body weight in db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Eating; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Mice; Mice, Inbred C57BL; Propiophenones; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Sprague-Dawley; Rats, Wistar; Streptozocin; Weight Loss | 2012 |
Flavone-based novel antidiabetic and antidyslipidemic agents.
Topics: Animals; Biological Availability; Cholesterol; Cricetinae; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Flavones; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Streptozocin; Structure-Activity Relationship; Triglycerides | 2012 |
Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents.
Topics: Animals; Anti-Infective Agents; Artemia; Bacteria; Bacterial Infections; Blood Glucose; Diabetes Mellitus, Experimental; Female; Fungi; Humans; Hypoglycemic Agents; Male; Molecular Docking Simulation; Mycoses; Rats; Rats, Wistar; Thiazolidinediones; Toxicity Tests | 2012 |
Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity.
Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Half-Life; Insulin Resistance; Male; Mice; PPAR gamma; Protein Structure, Tertiary; Quinolines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Structure-Activity Relationship; Sulfonamides | 2013 |
Discovery of novel bromophenol 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(isobutoxymethyl)benzyl)benzene-1,2-diol as protein tyrosine phosphatase 1B inhibitor and its anti-diabetic properties in C57BL/KsJ-db/db mice.
Topics: Animals; Benzhydryl Compounds; Catechols; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Mice, Obese; Molecular Structure; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Recombinant Proteins; Structure-Activity Relationship | 2013 |
Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Liver; Molecular Docking Simulation; Molecular Structure; PPAR gamma; Rats; Rats, Wistar; Risk Assessment; Streptozocin; Thiazolidinediones | 2014 |
Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists.
Topics: Animals; Blood Glucose; Computer Simulation; Diabetes Mellitus, Experimental; Drug Design; Female; Gene Expression Regulation; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Liver; Male; Molecular Docking Simulation; Molecular Structure; Oxadiazoles; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2014 |
Novel benzenesulfonylureas containing thiophenylpyrazoline moiety as potential antidiabetic and anticancer agents.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Line; Cell Proliferation; Diabetes Mellitus, Experimental; Drug Screening Assays, Antitumor; Glucose Tolerance Test; Hypoglycemic Agents; Mice; Molecular Docking Simulation; PPAR gamma; Pyrazoles; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfonylurea Compounds | 2014 |
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Design; Hep G2 Cells; Humans; Indoleacetic Acids; Mice; Mice, Mutant Strains; Molecular Structure | 2015 |
Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists.
Topics: Adipocytes; Adipose Tissue, White; Alcohols; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; Fasting; Gene Expression Regulation; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Indoleacetic Acids; Insulin; Liver; Male; Mice; Microsomes, Liver; PPAR delta; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2015 |
Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; PPAR gamma; Pyrazoles; Rats; Rats, Wistar; Streptozocin; Structure-Activity Relationship; Sulfonylurea Compounds | 2015 |
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents.
Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Molecular Structure; Murraya; Muscle Fibers, Skeletal; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Streptozocin | 2016 |
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Structure; Piperidines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; Spiro Compounds; Structure-Activity Relationship | 2016 |
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
Topics: Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; Humans; Hypoglycemic Agents; Molecular Docking Simulation; PPAR gamma; Protein Binding; Protein Structure, Tertiary; Quantitative Structure-Activity Relationship; Rats; Sulfonylurea Receptors; Thermodynamics | 2017 |
Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; ERRalpha Estrogen-Related Receptor; Hypoglycemic Agents; Indazoles; Ligands; Male; Mice; Mice, Obese; Molecular Structure; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Estrogen; Structure-Activity Relationship | 2017 |
Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Humans; Hypoglycemic Agents; Mice; Molecular Structure; Pyrroles; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2018 |
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Topics: Animals; CHO Cells; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucose Tolerance Test; HEK293 Cells; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Mice, Obese; Models, Molecular; Molecular Structure; PPAR delta; PPAR gamma; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2018 |
Structure-activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy.
Topics: Alkaloids; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Hep G2 Cells; Humans; Hypoglycemic Agents; Kidney; Male; Matrines; Mice, Inbred C57BL; Molecular Structure; Pancreas; Quinolizines; Structure-Activity Relationship | 2020 |
Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypoglycemic Agents; Male; Molecular Structure; NF-kappa B; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Streptozocin; Structure-Activity Relationship | 2021 |
Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Design; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Molecular Structure; PPAR gamma; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulindac | 2021 |
Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Topics: Animals; Diabetes Mellitus, Experimental; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Discovery; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Molecular Structure; Organic Chemicals; PPAR delta; PPAR gamma; Rats; Rats, Sprague-Dawley; Streptozocin; Structure-Activity Relationship | 2021 |
Effects of Moringa Oleifera Leaf Extract Plus Rosiglitazone on Serum Leptin and Glucose and Lipid Metabolism in Type 2 Diabetic Rats.
Topics: Animals; beta Catenin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Leptin; Lipid Metabolism; Lipids; Male; Moringa oleifera; Plant Extracts; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tumor Necrosis Factor-alpha | 2023 |
Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Ligands; Mice; Molecular Docking Simulation; PPAR gamma; PPAR-gamma Agonists; Rosiglitazone; Thiazolidinediones; Weight Gain | 2023 |
In Silico Design, Synthesis and Evaluation of Novel Series of Benzothiazole- Based Pyrazolidinediones as Potent Hypoglycemic Agents.
Topics: Animals; Benzothiazoles; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; Hypoglycemic Agents; Models, Molecular; Molecular Structure; PPAR gamma; Rats; Rosiglitazone; Structure-Activity Relationship | 2020 |
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Hypoglycemic Agents; Insulin; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Plant Roots; Polysaccharides; Pueraria; Random Allocation; Rosiglitazone; Signal Transduction | 2021 |
Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations.
Topics: Animals; Apoptosis; Blood Glucose; Cell Differentiation; Cell Proliferation; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Secretion; Insulin-Secreting Cells; Islets of Langerhans; Metformin; Mice; Rosiglitazone | 2022 |
Beneficial effects of rosiglitazone and losartan combination in diabetic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antioxidants; Aorta; Diabetes Mellitus, Experimental; Drug Interactions; Losartan; Male; Oxidative Stress; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2018 |
Codonopsis lanceolata Water Extract Increases Hepatic Insulin Sensitivity in Rats with Experimentally-Induced Type 2 Diabetes.
Topics: 3T3-L1 Cells; Adiposity; Animals; Biomarkers; Blood Glucose; Codonopsis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Energy Metabolism; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Pancreatectomy; Phosphorylation; Phytotherapy; Plant Extracts; Plants, Medicinal; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Solvents; Thiazolidinediones; Time Factors; Water | 2017 |
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Topics: Animals; Antioxidants; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Hypoglycemic Agents; Insulin; Kidney; Lipid Peroxidation; Nicotinamide Phosphoribosyltransferase; Obesity; Oxidative Stress; PPAR gamma; Rats, Wistar; Rosiglitazone; Signal Transduction; Streptozocin | 2018 |
Antidepressant and anxiolytic like effects of Urtica dioica leaves in streptozotocin induced diabetic mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Autophagy; Brain-Derived Neurotrophic Factor; Cyclin D1; Depression; Diabetes Mellitus, Experimental; Down-Regulation; Hippocampus; Hypoglycemic Agents; Male; Mice; Plant Extracts; Plant Leaves; Proto-Oncogene Proteins c-bcl-2; Rosiglitazone; Tumor Necrosis Factor-alpha; Urtica dioica | 2018 |
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Hypoglycemic Agents; Insulin Resistance; Male; Nicotinamide Phosphoribosyltransferase; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Spectrophotometry, Atomic; Thiazolidinediones; Trace Elements | 2018 |
Rosiglitazone up-regulates glial fibrillary acidic protein via HB-EGF secreted from astrocytes and neurons through PPARγ pathway and reduces apoptosis in high-fat diet-fed mice.
Topics: Animals; Apoptosis; Astrocytes; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Glial Fibrillary Acidic Protein; Heparin-binding EGF-like Growth Factor; Hypoglycemic Agents; Mice; Neurons; PPAR gamma; Rosiglitazone; Signal Transduction; Up-Regulation | 2019 |
Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.
Topics: Animals; Aorta, Abdominal; Cardiovascular Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression; Humans; Hypoglycemic Agents; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phytotherapy; Rosiglitazone; Signal Transduction | 2018 |
Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain.
Topics: 3T3-L1 Cells; Analgesics; Animals; Antioxidants; Cell Death; Diabetes Mellitus, Experimental; Diabetic Neuropathies; gamma-Aminobutyric Acid; Glucose; Hep G2 Cells; Humans; Hyperalgesia; Lipid Metabolism; Male; Mice; Motor Skills; Neuralgia; Pain Threshold; Pregabalin; Rosiglitazone; Terfenadine; Thiazolidinediones | 2013 |
Comparative study of the effect of ethanolic extract of Swietenia mahagoni seeds with rosiglitazone on experimentally induced diabetes mellitus in rats.
Topics: Alloxan; Animals; Bangladesh; Blood Glucose; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Male; Meliaceae; Phytotherapy; Plant Extracts; Rats; Rats, Long-Evans; Rosiglitazone; Seeds; Thiazolidinediones | 2013 |
Antihyperglycemic effect of carvacrol in combination with rosiglitazone in high-fat diet-induced type 2 diabetic C57BL/6J mice.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Cymenes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Monoterpenes; Rosiglitazone; Thiazolidinediones | 2014 |
Systems pharmacology of adverse event mitigation by drug combinations.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Blood Coagulation; Confounding Factors, Epidemiologic; Databases as Topic; Diabetes Mellitus, Experimental; Drug Combinations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Exenatide; Heart Function Tests; Humans; Mice; Myocardial Infarction; Peptides; Plasminogen Activator Inhibitor 1; Rosiglitazone; Systems Biology; Thiazolidinediones; Thrombelastography; Ultrasonography; United States; United States Food and Drug Administration; Venoms | 2013 |
Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Glucuronidase; Kidney; Klotho Proteins; Male; PPAR gamma; Rats, Wistar; Receptor, Fibroblast Growth Factor, Type 1; Rosiglitazone; Thiazolidinediones | 2014 |
Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model.
Topics: Animals; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Wistar; Rosiglitazone; Spirulina; Thiazolidinediones | 2013 |
Urtica dioica extract attenuates depressive like behavior and associative memory dysfunction in dexamethasone induced diabetic mice.
Topics: Animals; Antidepressive Agents; Association Learning; Avoidance Learning; Blood Glucose; Corticosterone; Depression; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Female; Glucose Transporter Type 4; Hippocampus; Hypoglycemic Agents; Immobilization; Insulin; Male; Maze Learning; Memory Disorders; Mice; Oxidative Stress; Phytotherapy; Plant Extracts; RNA, Messenger; Rosiglitazone; Stress, Psychological; Swimming; Thiazolidinediones; Urtica dioica | 2014 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Humulus; Hypoglycemic Agents; Insulin; Insulin Resistance; Macrophages; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Monocytes; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Novel effects of rosiglitazone on SMAD2 and SMAD3 signaling in white adipose tissue of diabetic rats.
Topics: Adipose Tissue, White; Animals; Diabetes Mellitus, Experimental; Male; PPAR gamma; Protein Serine-Threonine Kinases; Rats; Rats, Zucker; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Rosiglitazone; Signal Transduction; Smad2 Protein; Smad3 Protein; Thiazolidinediones; Transforming Growth Factor beta | 2014 |
Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ).
Topics: Animals; Body Weight; Cardiomyopathies; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Insulin; Male; Myocardium; Myocytes, Cardiac; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2015 |
Rosiglitazone increases cerebral klotho expression to reverse baroreflex in type 1-like diabetic rats.
Topics: Administration, Oral; Animals; Baroreflex; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucuronidase; Heart Rate; Humans; Injections, Intraventricular; Klotho Proteins; Male; Medulla Oblongata; Rats, Wistar; Recombinant Proteins; Rosiglitazone; Streptozocin; Thiazolidinediones | 2014 |
Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits.
Topics: Alloxan; Animals; Atrial Fibrillation; Atrial Function, Left; Atrial Remodeling; Biomarkers; Cardiac Pacing, Artificial; Diabetes Mellitus, Experimental; Fibrosis; Heart Atria; Hypoglycemic Agents; Inflammation Mediators; Oxidative Stress; Rabbits; Rosiglitazone; Thiazolidinediones; Time Factors | 2014 |
Phosphatase and tension homolog overexpression in insulin resistant diabetic adipose tissue.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Mice; Mice, Inbred C57BL; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones | 2014 |
Effects of Bofu-Tsusho-San on diabetes and hyperlipidemia associated with AMP-activated protein kinase and glucose transporter 4 in high-fat-fed mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, High-Fat; Down-Regulation; Drugs, Chinese Herbal; Fatty Acid Synthases; Gluconeogenesis; Glucose Transporter Type 4; Hyperlipidemias; Liver; Male; Mice; Mice, Inbred C57BL; Phosphorylation; PPAR alpha; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones | 2014 |
Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?
Topics: Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycated Hemoglobin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Kidney; Lipid Peroxides; Peroxisome Proliferator-Activated Receptors; Pravastatin; Rats; Rosiglitazone; Thiazolidinediones; Transferrin; Tumor Necrosis Factor-alpha | 2014 |
Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF-α.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Dyslipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Rats; Rosiglitazone; Streptozocin; Thiazolidinediones; Tumor Necrosis Factor-alpha; Xanthones | 2014 |
Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice.
Topics: Animals; Blood Glucose; Body Weight; Circadian Clocks; Diabetes Mellitus, Experimental; Fasting; Female; Gene Expression Regulation; Glucose Tolerance Test; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Pregnancy; Rosiglitazone; Thiazolidinediones | 2015 |
Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Benzamides; Cell Differentiation; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Experimental; Disease Models, Animal; Hyperglycemia; Indoles; Mice; Osteoblasts; Osteogenesis; Phosphorylation; PPAR gamma; Protein Binding; Rosiglitazone; Thiazolidinediones | 2015 |
Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
Topics: 3T3-L1 Cells; Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; Female; HEK293 Cells; Humans; Hypoglycemic Agents; Ligands; Liver; Male; Mice; Molecular Docking Simulation; Molecular Structure; Pioglitazone; PPAR gamma; Protein Binding; Rats, Wistar; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transfection | 2015 |
Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; 3T3-L1 Cells; Adipogenesis; Animals; Diabetes Mellitus, Experimental; Glucose; Mice; Mice, Obese; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2015 |
Rosiglitazone Attenuates Memory Impairment in Aged Rat with Diabetes by Inhibiting NF-kappa B Signal Pathway Activation.
Topics: Aging; Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Memory Disorders; NF-kappa B; Rats; Rats, Wistar; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2015 |
Herbal formulation, DIA-2 and Rosiglitazone ameliorates hyperglycemia and hepatic steatosis in type 2 diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diet, High-Fat; Fatty Liver; Hyperglycemia; Hypoglycemic Agents; Liver Diseases; Plant Extracts; Random Allocation; Rats; Rosiglitazone; Thiazolidinediones | 2015 |
Protective Effects of MDG-1, a Polysaccharide from Ophiopogon japonicus on Diabetic Nephropathy in Diabetic KKAy Mice.
Topics: Administration, Oral; Animals; Blood Glucose; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Administration Schedule; Gene Expression Regulation; Hypoglycemic Agents; Kidney; Mice; Polysaccharides; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Triglycerides | 2015 |
Resolution of Inflammation by Resolvin D1 Is Essential for Peroxisome Proliferator-activated Receptor-γ-mediated Analgesia during Postincisional Pain Development in Type 2 Diabetes.
Topics: Analgesia; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Docosahexaenoic Acids; Hypoglycemic Agents; Inflammation; Macrophages; Male; Mice; Pain, Postoperative; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2015 |
Therapeutic window of globular adiponectin against cerebral ischemia in diabetic mice: the role of dynamic alteration of adiponectin/adiponectin receptor expression.
Topics: Adiponectin; Animals; Apoptosis; Brain Ischemia; Caspase 12; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Injections, Intraventricular; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Protein Serine-Threonine Kinases; Receptors, Adiponectin; Reperfusion Injury; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factor CHOP | 2015 |
Protective Effects of Red Guava on Inflammation and Oxidative Stress in Streptozotocin-Induced Diabetic Mice.
Topics: Animals; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Experimental; Hyperglycemia; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Oxidative Stress; Plant Extracts; Psidium; Rosiglitazone; Streptozocin; Taiwan; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2015 |
Urtica dioica modulates hippocampal insulin signaling and recognition memory deficit in streptozotocin induced diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Female; Glucose Transporter Type 4; Hippocampus; Hypoglycemic Agents; Male; Memory Disorders; Mice; Neurons; Oxidative Stress; Plant Extracts; Protein Transport; Recognition, Psychology; Rosiglitazone; Signal Transduction; Thiazolidinediones; Urtica dioica | 2016 |
Effect of Vanadyl Rosiglitazone, a New Insulin-Mimetic Vanadium Complexes, on Glucose Homeostasis of Diabetic Mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Drinking Behavior; Feeding Behavior; Homeostasis; Insulin; Male; Metformin; Mice; Quercetin; Rosiglitazone; Spectrophotometry, Infrared; Thiazolidinediones; Trehalose; Vanadium | 2016 |
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice.
Topics: Adipocytes; Animals; Biomarkers, Tumor; Cell Dedifferentiation; Cell Differentiation; Cell Lineage; Cell Proliferation; Cell Transformation, Neoplastic; Diabetes Mellitus, Experimental; Diamines; Dibenzazepines; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lipid Metabolism; Liposarcoma; Metabolic Syndrome; Mice, Inbred C57BL; PPAR gamma; Precancerous Conditions; PTEN Phosphohydrolase; Receptors, Notch; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Xenograft Model Antitumor Assays | 2016 |
Activation of PPAR-γ reduces HPA axis activity in diabetic rats by up-regulating PI3K expression.
Topics: Adrenocorticotropic Hormone; Animals; Cell Count; Corticosterone; Diabetes Mellitus, Experimental; Down-Regulation; Hypertrophy; Hypothalamo-Hypophyseal System; Male; Phosphatidylinositol 3-Kinases; Pituitary-Adrenal System; PPAR gamma; Pro-Opiomelanocortin; Rats, Wistar; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2016 |
Long-term consumption of saponins derived from Platycodi radix (22 years old) enhances hepatic insulin sensitivity and glucose-stimulated insulin secretion in 90 % pancreatectomized diabetic rats fed a high-fat diet.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dietary Fats; Glucose; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Korea; Liver; Male; Pancreatectomy; Plant Extracts; Platycodon; Rats; Rats, Sprague-Dawley; Rosiglitazone; Saponins; Thiazolidinediones; Time Factors | 2009 |
Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Female; Gene Expression; Genomics; Growth Hormone; Hyperalgesia; Hypoglycemic Agents; Male; Mice; Mice, Inbred DBA; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Promoter Regions, Genetic; Rosiglitazone; Thiazolidinediones | 2008 |
Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.
Topics: Animals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Gene Expression Profiling; Insulin; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.
Topics: Albuminuria; Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Agents; Male; Mice; Mice, Inbred DBA; Oxidative Stress; Podocytes; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones; Urine | 2008 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Chaperonin 60; Diabetes Mellitus, Experimental; Disease Models, Animal; Fructose; Gene Expression; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Myocardium; Rats; Rats, Sprague-Dawley; Rosiglitazone; Streptozocin; Thiazolidinediones | 2009 |
Pharmacodynamic interaction of Momordica charantia with rosiglitazone in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Interactions; Glucose Tolerance Test; Male; Momordica charantia; Plant Extracts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Streptozocin; Thiazolidinediones | 2009 |
The role of rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study.
Topics: Animals; Diabetes Mellitus, Experimental; Hormones; Hypoglycemic Agents; Immunohistochemistry; In Situ Hybridization; Islets of Langerhans; Male; Peptides; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2008 |
The effects of rosiglitazione on renal artery endothelium in diabetic rats.
Topics: Animals; Blood Glucose; Cell Adhesion; Diabetes Mellitus, Experimental; Endothelium, Vascular; Female; Hyperglycemia; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Reference Values; Renal Artery; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression.
Topics: Albuminuria; Animals; Case-Control Studies; Diabetes Mellitus, Experimental; Disease Models, Animal; Hypoglycemic Agents; Kidney; Male; Matrix Metalloproteinase 9; Rats; Rats, Wistar; Retinol-Binding Proteins; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; DNA-Binding Proteins; Down-Regulation; Drug Interactions; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Hypolipidemic Agents; Liver X Receptors; Male; Mice; Orphan Nuclear Receptors; Phosphoenolpyruvate Carboxykinase (GTP); PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides | 2009 |
Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.
Topics: Animals; Cytoprotection; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Drug Evaluation, Preclinical; Gene Expression Regulation; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Kidney; Male; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Streptozocin; Thiazolidinediones | 2008 |
Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Experimental; Diet; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Male; Malonyl Coenzyme A; Muscle, Skeletal; Rats; Rats, Inbred OLETF; Rosiglitazone; Thiazolidinediones | 2009 |
Anti-diabetic effects of water extract and crude polysaccharides from tuberous root of Liriope spicata var. prolifera in mice.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liriope Plant; Male; Mice; Mice, Inbred BALB C; Phytotherapy; Plant Extracts; Plant Roots; Polysaccharides; Rosiglitazone; Thiazolidinediones; Triglycerides | 2009 |
Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Energy Metabolism; Feeding Behavior; Glucose Intolerance; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondria; Motor Activity; Muscle, Skeletal; Proteins; Proto-Oncogene Proteins c-akt; Recombinant Proteins; Rosiglitazone; Signal Transduction; Thiazolidinediones; Up-Regulation | 2009 |
Insulin sensitizing activity of ethyl acetate fraction of Acorus calamus L. in vitro and in vivo.
Topics: Acetates; Acorus; Administration, Oral; Animals; Diabetes Mellitus, Experimental; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Medicine, Traditional; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle Fibers, Skeletal; Plant Extracts; Rosiglitazone; Thiazolidinediones; Weight Gain | 2009 |
Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.
Topics: Adiponectin; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2009 |
Pluronic L-81 ameliorates diabetic symptoms in db/db mice through transcriptional regulation of microsomal triglyceride transfer protein.
Topics: Animals; Carrier Proteins; Cell Line; Cholesterol; Diabetes Mellitus, Experimental; Drinking; Eating; Gene Expression Regulation; Humans; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Poloxamer; Rosiglitazone; Surface-Active Agents; Thiazolidinediones; Triglycerides; Weight Loss | 2009 |
Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
Topics: Animals; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dinoprostone; Gastric Mucosa; Hypoglycemic Agents; Indomethacin; Male; Malondialdehyde; Metformin; Mucins; Nitric Oxide; Rats; Rats, Wistar; Rosiglitazone; Stomach Ulcer; Thiazolidinediones | 2010 |
Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies.
Topics: Animals; Blotting, Western; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Experimental; Enzyme Activation; Fibrinolytic Agents; Hypoglycemic Agents; Male; Metformin; Osteoblasts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Stem Cells; Thiazolidinediones | 2010 |
[Protective effect of rosiglitazone sodium on islet beta-cell of STZ induced diabetic rats through JNK pathway].
Topics: Animals; Apoptosis; Cells, Cultured; Diabetes Mellitus, Experimental; Islets of Langerhans; Male; MAP Kinase Kinase 4; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Streptozocin; Thiazolidinediones | 2009 |
Spirulina protects against rosiglitazone induced osteoporosis in insulin resistance rats.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Bone Density; Dexamethasone; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; Male; Osteoporosis; Rats; Rats, Wistar; Rosiglitazone; Spirulina; Thiazolidinediones | 2010 |
Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
Topics: Animals; Apoptosis; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Fenofibrate; Hypertrophy, Left Ventricular; Hypolipidemic Agents; Male; Myocytes, Cardiac; Oxidative Stress; PPAR alpha; PPAR gamma; Rats; Rosiglitazone; Streptozocin; Thiazolidinediones | 2010 |
The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Hypoglycemic Agents; Immunosuppressive Agents; Male; Protein Phosphatase 2; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sirolimus; Thiazolidinediones; Transcription Factors; Transforming Growth Factor beta1 | 2010 |
Obesity: New life for antidiabetic drugs.
Topics: Adipose Tissue; Animals; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Experimental; Dietary Fats; Humans; Insulin; Ligands; Mice; Obesity; Phosphorylation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.
Topics: Adipose Tissue; Amino Acid Sequence; Animals; Cell Line; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Experimental; Dietary Fats; Humans; Insulin; Ligands; Mice; Models, Molecular; Obesity; Phosphorylation; Phosphoserine; PPAR gamma; Protein Conformation; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells.
Topics: Animals; Blotting, Western; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Hypoglycemic Agents; Infant; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C57BL; Neurons; Phosphorylation; Polymerase Chain Reaction; PPAR gamma; Rats; Rats, Inbred OLETF; Rosiglitazone; tau Proteins; Thiazolidinediones; Transfection; Treatment Outcome | 2010 |
Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.
Topics: Acyl-CoA Dehydrogenase; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; CD36 Antigens; Cholesterol; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; Fatty Acid Transport Proteins; Gene Expression Regulation; Hypoglycemic Agents; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pioglitazone; Rosiglitazone; Thiazolidinediones; Triglycerides | 2010 |
Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
Topics: Albuminuria; Animals; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Kidney; Macrophages; Male; Membrane Proteins; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.
Topics: Animals; Antioxidants; Berberine; Coptis; Cyclin T; Cyclin-Dependent Kinase 9; Diabetes Mellitus, Experimental; Diet; Drugs, Chinese Herbal; Enzymes; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Peroxidation; Liver; Male; Malondialdehyde; Phytotherapy; Positive Transcriptional Elongation Factor B; Rats; Rats, Wistar; Rhizome; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2011 |
A study comparing the effects of rosiglitazone and/or insulin treatments on streptozotocin induced diabetic (type I diabetes) rat aorta and cavernous tissues.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glutathione; Inflammation; Insulin; Lipid Peroxidation; Male; Muscle Relaxation; Penis; Rats; Rosiglitazone; Thiazolidinediones | 2011 |
Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Topics: Animals; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Thiazolidinediones | 2011 |
Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Hypoglycemic Agents; In Situ Nick-End Labeling; Male; Microscopy, Confocal; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Rosiglitazone; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones | 2011 |
The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Hypolipidemic Agents; Lipids; Male; Pyrroles; Rats; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Aorta; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Endothelium, Vascular; Hypoglycemic Agents; Male; Mice; Mice, Obese; Nitric Oxide; Nitric Oxide Synthase Type III; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2011 |
PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.
Topics: Adipose Tissue; Animals; Cardiovascular Diseases; Cell Line; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Liver; Mice; Plasminogen Activator Inhibitor 1; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcriptional Activation | 2011 |
Rosiglitazone protects diabetic rats from liver destruction.
Topics: Animals; Apoptosis; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Fas Ligand Protein; Fatty Liver; In Situ Nick-End Labeling; Liver; Liver Diseases; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2011 |
Glyceollin-containing fermented soybeans improve glucose homeostasis in diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Fermentation; Glucose Tolerance Test; Glycine max; Glycogen; Homeostasis; Hypoglycemic Agents; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Peroxisome Proliferator-Activated Receptors; Phosphorylation; Pterocarpans; Rosiglitazone; Thiazolidinediones; Triglycerides | 2012 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2012 |
Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats.
Topics: Alloxan; Animals; Anti-Inflammatory Agents; Antioxidants; Catalase; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glutathione; Interleukin-6; Kidney; Lipid Peroxidation; Malondialdehyde; Metformin; Oxidative Stress; Phytotherapy; Plant Extracts; Rats; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Trigonella | 2012 |
Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.
Topics: Adipokines; Animals; Blood Glucose; Body Weight; Chemokines; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Kidney; Male; Pioglitazone; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Chemokine; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2012 |
Biodegradable anionic acrylic resin based hollow microspheres of moderately water soluble drug rosiglitazone maleate: preparation and in vitro characterization.
Topics: Acrylic Resins; Animals; Biological Availability; Diabetes Mellitus, Experimental; Drug Compounding; Emulsions; Hypoglycemic Agents; Male; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polymethacrylic Acids; Random Allocation; Rats; Rosiglitazone; Solubility; Solvents; Spectroscopy, Fourier Transform Infrared; Thiazolidinediones | 2012 |
Hypoglycemic effect and mechanism of a proteoglycan from ganoderma lucidum on streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fruiting Bodies, Fungal; Hypoglycemic Agents; Insulin; Lipids; Liver; Male; Metformin; Muscle, Skeletal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proteoglycans; Rats; Rats, Sprague-Dawley; Reishi; Rosiglitazone; Thiazolidinediones | 2012 |
Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glucose Transporter Type 4; Hypoglycemic Agents; Male; Myocardium; NADPH Oxidases; Phosphorylation; Random Allocation; Rats; Rats, Wistar; Receptors, Adiponectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Streptozocin; Thiazolidinediones | 2012 |
Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
Topics: Animals; Blood Glucose; Blood Pressure; Blood Vessels; Calcium; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Male; Nitric Oxide; Potassium Chloride; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides | 2012 |
Activation of PPARγ by restores mast cell numbers and reactivity in alloxan-diabetic rats by reducing the systemic glucocorticoid levels.
Topics: Animals; Apoptosis; Cell Count; Cell Differentiation; Cell Proliferation; Cushing Syndrome; Diabetes Mellitus, Experimental; Glucocorticoids; Male; Mast Cells; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2012 |
Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists.
Topics: Animals; Benzaldehydes; Computer Simulation; Coumarins; Diabetes Mellitus, Experimental; Esters; Hydantoins; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Models, Molecular; Oxazoles; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Streptozocin; Thiazolidinediones | 2012 |
MDG-1, a polysaccharide from Ophiopogon japonicus exerts hypoglycemic effects through the PI3K/Akt pathway in a diabetic KKAy mouse model.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Inbred C57BL; Ophiopogon; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Plant Roots; Polysaccharides; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides | 2012 |
Study of hypoglycemic activity of Subetta and rosiglitazone on the model of streptozotocin-induced diabetes mellitus in rats.
Topics: Animals; Antibodies; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Rats; Rosiglitazone; Thiazolidinediones | 2012 |
Effects of rosiglitazone with insulin combination therapy on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Glycated Hemoglobin; Heart Ventricles; Hypoglycemic Agents; Insulin; Ligands; Lipids; Male; Myocardium; Nitric Oxide; Oxidative Stress; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2012 |
[Reduced expression and secretion of apolipoprotein M in fat-fed, streptozotocin-diabetic rats is partially reversed by an artificial ligand of PPARγ].
Topics: Animals; Apolipoproteins; Apolipoproteins M; Diabetes Mellitus, Experimental; Dietary Fats; Lipocalins; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2012 |
Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models.
Topics: Animals; Biguanides; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Injections, Intraventricular; Injections, Spinal; Metformin; Mice; Mice, Inbred ICR; Pioglitazone; Rosiglitazone; Streptozocin; Thiazolidinediones | 2012 |
Quantitative histopathological assessment of retardation of islets of langerhans degeneration in rosiglitazone-dosed obese ZDF rats using combined insulin and collagens (I and III) immunohistochemistry with automated image analysis and statistical modelin
Topics: Algorithms; Animals; Collagen Type I; Collagen Type III; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Image Processing, Computer-Assisted; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Models, Statistical; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2013 |
Effects of neferine on CCL5 and CCR5 expression in SCG of type 2 diabetic rats.
Topics: Analysis of Variance; Animals; Benzylisoquinolines; Blood Glucose; Blood Pressure; Chemokine CCL5; Diabetes Mellitus, Experimental; Disease Models, Animal; Fasting; Female; Gene Expression Regulation; Heart Rate; Hypoglycemic Agents; Insulin; Lipid Metabolism; Lipoproteins, HDL; Male; Neural Conduction; Rats; Rats, Sprague-Dawley; Receptors, CCR5; RNA, Messenger; Rosiglitazone; Superior Cervical Ganglion; Thiazolidinediones | 2013 |
Rosiglitazone enhances neovascularization in diabetic rat ischemic hindlimb model.
Topics: Animals; Diabetes Mellitus, Experimental; Hindlimb; Male; Models, Biological; Neovascularization, Physiologic; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2012 |
Plant extracts of winter savory, purple coneflower, buckwheat and black elder activate PPAR-γ in COS-1 cells but do not lower blood glucose in Db/db mice in vivo.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Echinacea; Fagopyrum; Female; Insulin; Mice; Plant Extracts; PPAR gamma; Rosiglitazone; Sambucus nigra; Satureja; Thiazolidinediones; Triglycerides | 2012 |
Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing human islet amyloid polypeptide.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Graft Survival; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Time Factors | 2013 |
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrinolytic Agents; Male; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats.
Topics: Angiogenesis Inhibitors; Animals; Aqueous Humor; Capillaries; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Hypoglycemic Agents; Rats; Rats, Sprague-Dawley; Retinal Vessels; Rosiglitazone; Thalidomide; Thiazolidinediones; Vascular Endothelial Growth Factor A | 2003 |
Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Administration Schedule; Drug Therapy, Combination; Insulin; Intubation, Gastrointestinal; Male; Pyrones; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Vanadates | 2003 |
Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice.
Topics: Acyl Coenzyme A; Animals; Anticholesteremic Agents; Biological Transport; Blotting, Western; Body Weight; Cattle; Deoxyglucose; Diabetes Mellitus, Experimental; Glucose; Insulin; Insulin Resistance; Ligands; Ligases; Mice; Muscle, Skeletal; Muscles; Organic Chemicals; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors; Triglycerides; Tyrosine; Ubiquitin-Protein Ligases | 2004 |
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Drug Therapy, Combination; Drug Tolerance; Eating; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Pentanoic Acids; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors | 2005 |
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Cinnamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fenofibrate; Gene Expression Regulation, Enzymologic; Glucose; Homozygote; Humans; Hyperlipidemias; In Vitro Techniques; Insulin; Intercellular Signaling Peptides and Proteins; Kinetics; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Models, Chemical; PPAR alpha; PPAR gamma; Protein Binding; Protein Isoforms; Rats; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Triglycerides; Two-Hybrid System Techniques | 2005 |
Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats.
Topics: Angiotensin II; Animals; Apoptosis; Cyclosporine; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Islets of Langerhans; Kidney; Osteopontin; Pancreatic Diseases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sialoglycoproteins; Thiazolidinediones; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Glucose; Glucose Tolerance Test; Glycogen; Hepatocytes; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Liver Glycogen; Male; Muscle, Skeletal; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2005 |
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Triglycerides; Vasculitis | 2005 |
Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones.
Topics: Acridines; Animals; Benzyl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Male; Mice; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Pharmacological profile of a novel, non-TZD PPARgamma agonist.
Topics: Adipocytes; Animals; Benzoxazines; Blood Glucose; Diabetes Mellitus, Experimental; Female; Gene Expression Regulation; Glycated Hemoglobin; Hepatocytes; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Lipid Metabolism; Male; Mice; Mice, Obese; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Triglycerides | 2005 |
Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Cholesterol; Cyclohexanes; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Metformin; Nateglinide; Phenylalanine; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Gene Expression; Gene Expression Profiling; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Multigene Family; Oligonucleotide Array Sequence Analysis; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA; Rosiglitazone; Thiazolidinediones | 2006 |
(+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Coronary Vessels; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Gene Expression; Hypoglycemic Agents; Kidney; Liver; Metabolic Syndrome; Obesity; Organ Size; Phenanthrenes; PPAR alpha; PPAR gamma; Random Allocation; Rats; Rats, Zucker; Risk Factors; Rosiglitazone; Selective Estrogen Receptor Modulators; Thiazolidinediones; Triglycerides | 2005 |
Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
Topics: Animals; Blood Glucose; Carotid Artery Diseases; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Down-Regulation; Endothelial Cells; Glycation End Products, Advanced; Insulin; Lipids; PPAR gamma; Rats; Rats, Zucker; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones; Tunica Intima | 2006 |
Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy.
Topics: Animals; Blood Glucose; Cell Line, Tumor; Cell Proliferation; Choriocarcinoma; Chorionic Gonadotropin; Diabetes Mellitus, Experimental; Female; Fibrinolytic Agents; Humans; Immunologic Factors; Mice; Mice, Inbred ICR; Placenta; PPAR gamma; Pregnancy; Pregnancy in Diabetics; Prostaglandin D2; Rosiglitazone; Thiazolidinediones; Trophoblasts; Vascular Endothelial Growth Factor A | 2007 |
[Protective effect of rosiglitazone on myocardium in diabetic cardiomyopathy of rats].
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Ligands; Male; Myocardium; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2006 |
Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.
Topics: Acetylcholine; Animals; Aorta; Arginine; Cells, Cultured; Diabetes Mellitus, Experimental; Endothelium, Vascular; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Muscle, Smooth, Vascular; Nitrates; Nitric Oxide Synthase; Nitrites; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Vasodilation | 2007 |
Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Topics: Animals; Blood Glucose; Blood-Retinal Barrier; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Fluorophotometry; Immunoenzyme Techniques; Intercellular Adhesion Molecule-1; Leukocytes; Leukostasis; Ligands; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Rats; Rats, Inbred BN; Retinal Vessels; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Up-Regulation; Vascular Endothelial Growth Factor A | 2006 |
Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.
Topics: Acetates; Animals; Area Under Curve; Blood Glucose; Cells, Cultured; Cholesterol; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Humans; Hydrolysis; Hypoglycemic Agents; Indans; Indicators and Reagents; Lipoproteins, HDL; Mice; PPAR alpha; PPAR delta; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2007 |
[Effects of rosiglitazone on the expression connective tissue growth factor in tubulointerstitium in KKA(y) mice].
Topics: Animals; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Female; Fibronectins; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Kidney Cortex; Kidney Tubules; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Up-Regulation | 2006 |
Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Pyrrolidines; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Male; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones | 2007 |
[Effects of Shengqi Jiangtang Granule on rat model of insulin resistance and its mechanism].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Drugs, Chinese Herbal; Endothelin-1; Hypoglycemic Agents; Insulin Resistance; Male; Phytotherapy; Protein Kinase C; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice.
Topics: Animals; Blood Glucose; Catalase; Cholesterol; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glutathione; Hypoglycemic Agents; Insulin; Kidney; Lipid Peroxidation; Male; Mice; Myocardium; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Thyroxine; Triglycerides; Triiodothyronine | 2007 |
Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Topics: Animals; Blood Glucose; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Energy Metabolism; Hypoglycemic Agents; Mice; Mice, Obese; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cell Adhesion Molecules; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Disease Models, Animal; Down-Regulation; Endothelial Cells; Humans; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Umbilical Veins; Vascular Cell Adhesion Molecule-1; Vasculitis | 2008 |
Effects of rosiglitazone on altered electrical left ventricular papillary muscle activities of diabetic rat.
Topics: Action Potentials; Analysis of Variance; Animals; Diabetes Mellitus, Experimental; Electric Stimulation; Heart; Heart Ventricles; Hypoglycemic Agents; In Vitro Techniques; Insulin Resistance; Male; Papillary Muscles; Potassium Channels; Rats; Rats, Wistar; Rosiglitazone; Streptozocin; Thiazolidinediones; Ventricular Function | 2008 |
Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Hypoglycemic Agents; Male; PPAR alpha; PPAR delta; PPAR gamma; Rats; Rats, Wistar; Retina; Rosiglitazone; Thiazolidinediones | 2007 |
The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glycated Hemoglobin; Heart Ventricles; Lipid Metabolism; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Rosiglitazone; Streptozocin; Thiazolidinediones; Tyrosine | 2008 |
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3 | 2000 |
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Cytoplasm; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Fibrinolysin; Glomerular Mesangium; Matrix Metalloproteinase Inhibitors; Plasminogen Activator Inhibitor 1; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Liver; Male; Muscle, Skeletal; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3 Cells; Adipocytes; Animals; Cycloheximide; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Hydroxysteroid Dehydrogenases; Kinetics; Leptin; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2001 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Topics: Animals; Cardiotonic Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lactic Acid; Male; Mitogen-Activated Protein Kinases; Monosaccharide Transport Proteins; Muscle Proteins; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |